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Abstract
Background: The increase in antibiotic resistant bacteria has led to renewed interest in development of alternative
antimicrobial compounds such as antimicrobial peptides (AMPs), either naturally-occurring or synthetically-derived.
Knowledge of the mode of action (MOA) of synthetic compounds mimicking the function of AMPs is highly
valuable both when developing new types of antimicrobials and when predicting resistance development. Despite
many functional studies of AMPs, only a few of the synthetic peptides have been studied in detail.
Results: We investigated the MOA of the lysine-peptoid hybrid, LP5, which previously has been shown to display
antimicrobial activity against Staphylococcus aureus. At concentrations of LP5 above the minimal inhibitory
concentration (MIC), the peptoid caused ATP leakage from bacterial cells. However, at concentrations close to the
MIC, LP5 inhibited the growth of S. aureus without ATP leakage. Instead, LP5 bound DNA and inhibited
macromolecular synthesis. The binding to DNA also led to inhibition of DNA gyrase and topoisomerase IV and
caused induction of the SOS response.
Conclusions: Our data demonstrate that LP5 may have a dual mode of action against S. aureus. At MIC
concentrations, LP5 binds DNA and inhibits macromolecular synthesis and growth, whereas at concentrations
above the MIC, LP5 targets the bacterial membrane leading to disruption of the membrane. These results add new
information about the MOA of a new synthetic AMP and aid in the future design of synthetic peptides with
increased therapeutic potential.
Background
Growing concern over the increase in multidrug resist-
ant bacteria has urged the interest for development of
new types and classes of antimicrobial compounds. One
such class is antimicrobial peptides (AMPs), also known
as host defence peptides, that are found in all multicellu-
lar organisms and form an important part of the innate
immune system [1]. They exhibit antimicrobial activity
against a wide range of pathogenic microorganisms, have
immune-modulatory effects and enhance the host de-
fence against pathogenic bacteria [2-4]. AMPs are usu-
ally small cationic and amphiphatic peptides comprised
of less than 40 amino acids with immense diversity in
sequence, secondary structure motifs, charge and/or the
abundance of certain specific amino acids [5]. Their ability
to selectively kill prokaryotic rather than eukaryotic cells,
make them promising candidates for drug development.
However, one drawback of most natural AMPs as thera-
peutics is their susceptibility to proteolytic degradation
[6]. To overcome this problem an approach known as
peptidomimetics has emerged in recent years by which
compounds are produced that mimic a peptide structure
and/or function but carries a modified backbone and/or
non-natural amino acids. The peptide-mimetic com-
pounds have been designed based on essential biophysical
characteristics of AMPs: charge, hydrophobicity, and
amphiphatic organization [7-9]. Oligomeric N-substituted
glycines, also known as peptoids, belong to the simpler
AMP-mimetic designs. They are structurally similar to α-
amino peptides, but the side chain is shifted to amide
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nitrogen instead of the α-carbon [10-12]. This feature of-
fers several advantages including protease stability [13],
and easy synthesis by the submonomer approach [11].
Previously, a study screening 20 lysine-peptoid hybrids
identified a hybrid displaying good antimicrobial activity
toward a wide range of clinically relevant bacteria, in-
cluding Staphylococcus aureus (S. aureus), in addition
to low cytotoxicity to mammalian cells [14,15]. The
lysine-peptoid hybrid LP5 (lysine-peptoid compound 5)
contains the peptoid core [N-(1-naphthalenemethyl)gly-
cyl]-[N-4-methylbenzyl)glycyl]-[N-(1-naphthalenemethyl)
glycyl]-N-(butyl)glycin amide and 5 lysines (Figure 1)
[14,15]. LP5 is thus potentially interesting as a lead struc-
ture in the development of new antimicrobials functioning
against pathogens like S. aureus which are increasingly be-
coming resistant toward conventional antibiotics [16].
Due to their cationic and amphiphatic nature, it is be-
lieved that most AMPs selectively kill bacteria by penetrat-
ing the negatively charged cell membrane leading to
membrane disintegration. However, during the last two
decades it has become apparent that some AMPs may also
act by other mechanisms without destruction of the cell
membrane, namely, acting on intracellular targets leading
to inhibition of enzymatic activities, cell wall synthesis and
RNA, DNA and protein synthesis [5,17,18].
The inhibition of RNA, DNA and protein synthesis in
bacteria is often the result of AMPs interacting with
DNA [19,20]. Additionally, interaction with DNA by the
hexapeptide WRWYCR and its D-enantiomers was shown
to interfere with DNA repair [21]. DNA repair damage
elicits the SOS response that is a conserved pathway es-
sential for DNA repair and restart of stalled or collapsed
replication forks, regulated by the repressor LexA and the
activator RecA [22,23].
In this study, we set out to investigate the mode of ac-
tion (MOA) of LP5 using the pathogenic bacterium
S. aureus. Collectively, our data suggest that LP5 has a
dual mode of action; at MIC values it is able to bind
DNA leading to inhibition of DNA biosynthesis, inhib-
ition of the function of topoisomerase IV (Topo IV) and
DNA gyrase and induction of the SOS response through
recA. However, when using concentrations above the
MIC, LP5 targets the bacterial membrane leading to dis-
ruption of the bacterial membrane.
Results and discussion
Determination of MIC of LP5 against S. aureus
Given that the lysine-peptoid LP5 has antimicrobial activ-
ity toward a number of bacterial and fungal pathogens, we
investigated how LP5 interacts with and affects the patho-
genic bacterium S. aureus. We tested the MIC of LP5
against two S. aureus strains, 8325–4, a laboratory strain
of human origin [24], and the clinically relevant commu-
nity acquired strain USA300 [25]. MIC was in the range of
16 to 32 μg/ml for both strains.
Permeabilization of the S. aureus membrane by LP5 is
concentration dependent
Many AMPs interact with the bacterial membrane, leading
to pore-formation and subsequently leakage of intracellu-
lar components [5]. Therefore, to determine whether LP5
influences S. aureus membrane structure, we investigated
membrane integrity by measuring ATP leakage. We found
that increasing concentrations of LP5 added to S. aureus
8325–4 at time-point 0, lead to a gradual increase in ATP
leakage from the cells (Figure 2). The addition of 1000
μg/ml of LP5 most likely resulted in an abrupt destruc-
tion of the bacterial membrane, since no intracellular
ATP was detectable and an immediate increase in extra-
cellular ATP was detected. However, at low concentra-
tions of LP5 only limited leakage of ATP was observed,
showing that the leakage of ATP is concentration
dependent. Thus, in this experiment we find that LP5
Figure 1 Chemical structure of the lysine-peptoid hybrid LP5.
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targets the membrane at high concentrations whereas little
effect on the membrane was seen at low concentrations.
These observations agree well with the killing kinetics
of LP5 against S. aureus (Figure 3). Here, we performed
dose-dependent time-kill assays at two concentrations
representing 1 ×MIC and 5 ×MIC (Figure 3). LP5 re-
duced the colony forming unit (CFU) counts by 2 log
units during the first 30 min of the experiment at 5 ×
MIC. Thereafter, the killing rate gradually decreased and
after the 5 h time course approached a total reduction of
CFU count by 4 log units. At 1 ×MIC LP5 did not re-
duce the CFU within the 5 h of exposure (Figure 3) and
the exposed bacteria resumed growth when transferred
to media without LP5 (data not shown). Thus, at this
concentration LP5 does not to kill S. aureus, instead it
prevents growth, indicating that LP5 does not affect the
cell membrane but rather has an intracellular target.
This notion is supported by the finding that concentra-
tions several fold above the MIC is needed to see ATP
leakage. Some AMPs can cause small membrane lesions,
which lead to transient leakage of protons and thereby
depletion of intracellular ATP, which would affect synthe-
sis of cellular molecules [26]. However, from our ATP
leakage experiment, it is clear that the intracellular level of
ATP does not decrease, until high concentrations of LP5
are used and increased ATP leakage is observed (Figure 2).
AMPs have previously been suggested to have multiple
targets, including both intracellular targets and the
membrane, depending on the concentration of the AMP
[18]. Indolicidin and the peptidomimetic oligo-acyl-lysine
(OAK) C12K-2β12 (OAKs: a group of AMPs composed of
amino fatty acids) induce membrane damage at magni-
tudes above their MICs, whereas around their MICs they
were both found to have intracellular targets [27-29].
LP5 inhibits macromolecular synthesis of DNA and binds
DNA in vitro
AMPs can affect the synthesis of macromolecules [30] and
since LP5 is likely to have an intracellular target, we inves-
tigated its effect on DNA synthesis. We assessed the ability
of S. aureus to incorporate radiolabeled thymidine into
DNA after exposure to concentrations of LP5 at either
1 ×MIC or 5 ×MIC. The incorporation was monitored
over a time period of 30 min and the DNA synthesis was
clearly inhibited within the first 5 min after addition of
LP5 at both 1 ×MIC and 5 ×MIC (Figure 4).
Previously it has been shown that the inhibition of
DNA synthesis by AMPs is associated with their DNA
binding [19,20,31]. Therefore, to clarify whether LP5 in-
hibits DNA synthesis by binding to bacterial DNA, a gel
retardation assay was performed. As shown in Figure 5,
gel retardation with plasmid DNA demonstrated that in
the absence of LP5 pRMC2 migrates as a plasmid. How-
ever, upon the addition of increasing concentrations of
LP5, the pRMC2 plasmid was no longer able to migrate
into the gel. This suggests that LP5 interacts with plas-
mid DNA and inhibits the migration of plasmid DNA.
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Figure 2 Measurement of ATP leakage from S. aureus 8325–4
after treatment with LP5. Measurement of intracellular (IC) and
extracellular (EC) ATP after treatment with increasing concentrations
of LP5 (0–1000 μg/ml).
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Figure 3 Kinetics of bacterial killing in vitro. S. aureus 8325–4
was incubated with LP5 at 0, 1 × MIC or 5 × MIC. CFU,
colony-forming units.
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Figure 4 LP5 inhibit bacterial macromolecular synthesis of
DNA. Effect of LP5 at 1 × MIC and 5 × MIC on DNA synthesis of S.
aureus 8325–4 measured by incorporation of radiolabelled
precursors [methyl-3H]thymidine. Data are one representative of
three independent experiments, which all gave similar results.
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From the gel retardation assay we observed that at LP5
concentrations well below the MIC value (2.5 μg/ml) LP5
interferes with the migration of plasmid DNA and at 20
μg/ml LP5 the plasmid DNA was altered to such an extent
that it no longer entered the gel. DNA binding is not a
general property of AMPs, since another peptide, plectasin,
did not bind to plasmid DNA in the same experiment (data
not shown). The ability of AMPs containing peptoid resi-
dues to translocate across lipid bilayers and bind to bacter-
ial DNA has been shown for KLW-L9,13a containing two
Nala (Alanine-peptoid) [32]. However, whether this is a
general MOA of peptoids still needs to be elucidated. Col-
lectively, these observations strongly support our hypoth-
esis that LP5 exert its MOA intracellularly by binding to
DNA and inhibiting DNA synthesis.
LP5 inhibits DNA gyrase and Topo IV and induces the
SOS response through the recA gene
Since LP5 inhibits DNA synthesis and binds DNA we
speculated that the DNA replication machinery was af-
fected by LP5. Some of the main players of bacterial
DNA replication are the type II topoisomerases, DNA
gyrase and Topo IV. DNA gyrase is responsible for the
removal of positive supercoils in front of the advancing
replication fork, whereas Topo IV decatenates the pre-
catenanes behind the replication fork [33]. To investi-
gate if the activity of these enzymes is influenced by LP5
in vitro, supercoiling and decatenation assays were
performed using S. aureus DNA gyrase and Topo IV, re-
spectively. The supercoiling and decatenation activity of
S. aureus DNA gyrase and Topo IV was measured in
the presence of various concentrations of LP5 with cip-
rofloxacin used as a positive control [34].
LP5 was inhibitory on both S. aureus DNA gyrase and
Topo IV in that the enzymes were unable to supercoil or
decatenate DNA, respectively (Figure 6). This suggests
that LP5 interferes with the activity of both enzymes.
However, because we found that LP5 binds to DNA, the
observed inhibition of the DNA gyrase and Topo IV is
likely due to the inaccessibility of the enzymes to bind to
DNA and exert their function possibly leading to stalled
replication forks.
Stalling of replication forks often lead to induction of
the SOS response in bacteria [35]. The ability to induce
the SOS response was determined by visualizing the β-
galactosidase synthesis from a recA-lacZ fusion using an
agar diffusion assay [36] (Figure 7). The result clearly dem-
onstrated an induction of the expression of recA in vitro
by LP5 monitored as a blue ring at the point of bacterial
growth (Figure 7(A)). Ciprofloxacin was used as a positive
control as it is known to induce recA expression in S. aur-
eus (Figure 7(B)) [37] and H2O was used as a negative
control (data not shown). The ability to induce the
1             2           3             4           5             6            7
Figure 5 LP5 binds to DNA. Gel retardation with S. aureus DNA.
Increasing amounts of LP5 were incubated with 100 ng pRMC2
plasmid DNA and run on an agarose gel. Lane 1: negative control
containing binding buffer. Lane 2–7: containing increasing amounts
of LP5 (2.5, 5, 10, 20, 40 and 80 μg/ml). The experiment is one
representative of four experiments, which all gave similar results.
A Lane 1 2 3 4 5 6 7 8
Gyr - + + + + + + +
Drug - - Cip LP5 LP5 LP5 LP5 LP5
µg/ml 0 0 33
B Lane 1 2 3 4 5 6 7 8
TopoIV - + + + + + + +
Drug - - Cip LP5 LP5 LP5 LP5 LP5
µg/ml 0 0 33
Figure 6 LP5 affects the supercoiling and decatenation activity
of S. aureus DNA. (A) The supercoiling reaction mixtures containing
relaxed DNA and S. aureus gyrase (Gyr) (Lane 2–8). Lane 1 served as
a negative control containing only relaxed DNA. Lane 3 served as a
positive control containing ciprofloxacin (Cip). Lane 4–8 containing
increasing concentration of LP5 (66.4 μg/ml to 331.8 μg/ml). (B) The
decatenation reaction mixtures containing kinetoplast DNA and S.
aureus Topo IV (Lane 2–8). Lane 1 served as a negative control
containing only relaxed DNA. Lane 3 served as a positive control
containing ciprofloxacin (Cip). Lane 4–8 containing increasing
concentration of LP5 (66.4 μg/ml to 331.8 μg/ml).
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SOS response was shown recently for the hexapeptide
WRWYCR that exerts its broad bactericidal activity by in-
ducing the SOS response through stalling of bacterial rep-
lications forks [36].
To our knowledge these results show for the first time
that a peptoid is able to bind DNA, induce the SOS re-
sponse and interfere with the functions of DNA gyrase
and Topo IV.
Conclusions
In conclusion, we propose a model in which LP5 exerts a
dual MOA. At 1 ×MIC the lysine-peptoid hybrid traverses
the cytoplasmic membrane of S. aureus without causing
lethal damage and binds the chromosomal DNA, inhibits
topo IV and DNA gyrase and thereby the replication
machinery by blocking the accessibility to DNA. The in-
hibitory effect on DNA replication induces the SOS re-
sponse leading to inhibition of growth. At concentrations
of 5 ×MIC and above, LP5 also targets the cell membrane
leading to leakage of intracellular compounds like ATP,
resulting in cell death. These results add new information
about the MOA of a new synthetic peptide, and advance
our knowledge of these compounds as potential anti-
microbial therapeutics.
Methods
Peptide synthesis
The synthesis of LP5 was performed using a combin-
ation of the sub-monomer approach and Fmoc SPPS, as
previously described [38].
Strains and culture conditions
Three S. aureus strains were used in this study: Strain
8325–4 [24], FPR3757 USA300 a multidrug resistant
community-acquired strain (CA-MRSA) implicated in out-
breaks of skin and soft tissue infection [25] and HI2682,
which contains a recA-lacZ fusion made in this study as
described below. The bacteria were grown in Tryptone Soy
Broth (TSB, CM0129 Oxoid). When appropriate, antibi-
otics were added at the following concentrations: 5 and
10 μg/ml tetracycline and 50 μg/ml ciprofloxacin (Sigma).
Minimum inhibitory concentration determination
The minimum inhibitory concentration (MIC) of LP5 was
determined using the modified microtiter broth dilution
assay for cationic antimicrobial peptides from Hancock
(http://cmdr.ubc.ca/bobh/methods/MODIFIEDMIC.html).
Briefly, serial 2- fold dilution of LP5 (at 10 times the re-
quired test concentration) was made in 0.2% bovine serum
albumin (Sigma, A7906) and 0.01% acetic acid in polypro-
pylene tubes. Overnight cultures of S. aureus 8325–4 and
FPR3757 USA300 were diluted in Mueller Hinton broth
(Oxoid, CM0405) to a final concentration of approximately
5 × 105 CFU/ml and 100 μl was added to each well of a 96-
well polypropylene microtiter plate. To each well was added
11 μl of the 2-fold serial diluted LP5. The plate was incu-
bated overnight and the MIC was read as the lowest con-
centration of peptide that inhibited visible growth of
S. aureus. The reported results are from three independent
experiments.
Determination of the effect of LP5 on the bacterial
envelope - ATP measurements
Pore formation as caused by peptide addition was deter-
mined by measuring ATP leakage from the bacterial cell
using a bioluminescence assay as previously described
[39]. S. aureus 8325–4 was grown in TSB at 37°C over-
night and then re-inoculated in TSB at 37°C. S. aureus
was harvested (3000 RPM, 10 min) at mid-exponential
phase (OD546 of 2.5 ± 0.1), washed once in 50 mM po-
tassium phosphate buffer pH 7.0 and once in 50 mM
HEPES buffer pH 7.0. The pellet was resuspended in
50 mM HEPES pH 7.0 to a final OD546 of 10. Bacteria
were stored on ice and used within 5 h. Bacteria were en-
ergized in 50 mM HEPES (pH 7.0) with 0.2% (w/v) glu-
cose and treated with various concentrations of LP5 up to
a concentration of 1000 μg/ml. ATP measurements were
performed at time-point 0. ATP was determined using a
bioluminescence kit (Sigma, FLAA-1KT) and a BioOrbit
1253 luminometer. Total ATP content was determined by
rapidly permeabilizing 20 μl cell suspension with 80 μl di-
methyl sulfoxide. The cell suspension was diluted in 4.9
ml sterile water, and ATP content was determined in
100 μl of the preparation as described by the manufac-
turer. To determine the extracellular ATP concentration,
the 20 μl cell suspension was mixed with 80 μl sterile
water and analysed as described above. Intracellular ATP
concentrations were calculated by using the intracellular
volumes of 0.85 μm3. The number of cells in suspension
was determined by plate spreading. The reported results
are from two independent experiments.
A B
Figure 7 LP5 induces recA expression in S. aureus. (A) LP5 or (B)
ciprofloxacin (positive control) was added to wells in TSB agar plates
containing the S. aureus 8325–4 derived lacZ reporter strain HI2682
(recA::lacZ). Incubation time was 18 h. Data are one representative of
three independent experiments, which all gave similar results.
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In vitro killing kinetics of S. aureus
S. aureus 8325–4 was grown overnight in TSB medium
and diluted 1:50 in TSB medium and allowed to grow to
OD600 of 0.2. LP5 was added to final concentrations
equally to one (16 μg/ml) and five times (80 μg/ml) the
MIC value, followed by incubation at 37°C while shaking.
A control without LP5 was included. At the specified time
points aliquots were diluted (serial 10-fold dilutions in sa-
line) and plated on TSB agar. CFU were counted after an
overnight incubation at 37°C. The reported results are
from three independent experiments.
Survival of S. aureus after LP5 exposure
The ability of S. aureus 8325–4 to resume growth after in-
cubation with 1 ×MIC was investigated as follows: bac-
teria were grown overnight in TSB medium and diluted
1:50 in TSB medium and allowed to grow to OD600 of 0.2
LP5 was added to a final concentration 1 ×MIC, followed
by incubation at 37°C while shaking. A control without
LP5 was included. After 3 h cells were harvested and
resuspended in fresh TSB medium and 3 × 100 μl cell sus-
pension was added to 100 μl TSB medium in a 96-well mi-
crotiter plate. Growth was monitored by measuring the
optical density at 600 nm every 20 min for 17 h by the
Gen5™ program (BioTek®). The reported results are from
two independent experiments.
Macromolecular synthesis and bacterial killing
Overnight cultures of S. aureus 8325–4 were diluted
1:50 in TSB and allowed to grow to OD600 of 0.2 1 μCi/
ml (37MBq) of [methyl-3H] thymidine was added to the
culture. After 10 min of incubation at 37°C, LP5 was
added at 1 ×MIC and 5 ×MIC. Samples of 500 μl were
removed immediately before addition of LP5 (0 min)
and at 5, 10, 20 and 30 min after addition of LP5 and
added to 2 volume of 99.9% ice cold EtOH and 0.1 vol-
ume of 3M sodium acetate (NaAc) pH 5.5 in order to
precipitate macromolecules. After overnight precipita-
tion at −20°C samples were collected by centrifugation
(12000 rpm, 10 min) and washed twice in 1 ml of ice
cold 70% EtOH. Samples were resuspended in 100 μl of
milliQ water and added to 4 ml scintillation vials with
EcoscintA liquid scintillation cocktail, and counts were
obtained in a Beckman scintillation counter for 5 min
for each sample using the tritium program. The reported
results are from three independent experiments.
DNA-binding analysis
Gel retardation analysis was performed as previously de-
scribed [40] by mixing 100 ng of plasmid DNA (pRMC2)
[41] isolated from S. aureus 8325–4 with increasing
amounts of LP5 in 20 μl binding buffer (5% w/v glycerol,
10 mM Tris, 1 mM EDTA, 1 mM dithiothreitol, 20 mM
KCl and 50 μg/ml bovine serum albumin). Reaction
mixtures were incubated 1 h at room temperature and
subjected to 1% agarose gel electrophoresis and visualised
using ethidium bromide. The reported results are one rep-
resentative of four independent experiments, showing
similar results.
Construction of recA-lacZ fusion
Plasmid pHI1496 carrying a lacZ gene was digested with
SmaI and XhoI (New England Biolabs) and ligated into
pCL25 (a vector carrying the L54a attachment site for inte-
gration into the lipase gene (geh) of the S. aureus chromo-
some) [42] digested with SmaI and SalI (New England
Biolabs). The recA promoter was amplified by PCR using
the primers RecA-BstBI-F (5′tatttcgaatacggcacctttaccgaaag
a3′) and RecA-BamHI-R (5′tatttcgaatacggcacctttaccgaaa
ga3′) and was cloned into pCR®2.1-TOPO® (Invitrogen).
The 663 bp recA sequence was excised from pCR®2.1-
TOPO® using BstBI and BamHI (New England Biolabs)
and cloned into BstBI/BamHI-cut lac-Z vector, to give
pMTC100 in E. coli DH5α. The pMTC100 plasmid was
electroporated into S. aureus RN4220 [43] and recom-
binants selected on 10 μg/ml tetracycline. Since the
pMTC100 do not contain a replicon active in S. aureus,
tetracycline resistant clones occur as a result of a recombin-
ation event between the plasmid insert and the host. Fi-
nally, the recA::lacZ fusion from RN4220 was transduced
into S. aureus 8325–4 using the Φ11 phage from S. aureus
8325 as the carrier [24], and selected on 5 μg/ml tetracyc-
line plates. The expected integrational event was confirmed
by colony-PCR using the primers RecA-BamHI-F (5′
tatggatcctgacacattaattgagcaagctgt3′) and LexA/lacZ-R (5′
cccattcgccattcagg3′). The strain is called HI2682.
Agar diffusion assay
The assay use a transcriptional reporter strain, HI2682,
carrying lacZ fused to recA. 30 μl of 13.33 mg/ml LP5,
0.05 mg/ml ciprofloxacin or H2O was tested in the agar
diffusion assay where the expression from the promoter of
recA is monitored as previously described [36]. Induction
of the recA gene was monitored as colour change. The
reported results are one representative of three independ-
ent experiments, showing similar results.
Supercoiling and decatenation assays
Supercoiling and decatenation assays were performed as
previously described [34] with minor modifications in
the reaction mixture content. In the reaction mixtures
we used 5 μg/ml tRNA, various concentrations (0; 66.4;
132.7; 199.1; 265.4; 331.8 μg/ml) of LP5 and added ei-
ther 100 fmol (as a tetramer) of S. aureus gyrase or
50 fmol of S. aureus Topo IV. In the control reaction
33 μg/ml ciprofloxacin was used instead of LP5. Add-
itionally, the DNA products were purified with phenol/
chloroform to deproteinize the reactions.
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